|
This page contains a list of all PQRI Working Groups. Detailed work plans and minutes from Working Group meetings are also highlighted.
Each Working Group is overseen by one of PQRI’s four Technical Committees. For more information about these Technical Committees, please click here.
Radio Frequency Identification Working Group (RFID WG)
(Chairs) Robert Seevers and Toby Massa
The RFID WG is looking at implications of using radio-frequency identification devices on boxes containing pharmaceutical products.
Future FDA RFID Guidance
Back To Top
Container/Closure Systems
(Chairs) Daniel Malinowski
The Container/Closure Systems WG is developing test methods and evaluation criteria in support of FDA's PACPAC guidance.
Draft Guidance for Industry Stability Testing of Drug Substances and Drug Products (Draft June 1998) http://www.fda.gov/cder/guidance/1707dft.pdf
Final Guidance for Industry Container Closure Systems for Packaging Human Drugs and Biologics (May 1999) http://www.fda.gov/cder/guidance/1714fnl.pdf
Final Guidance for Industry Changes to an Approved NDA and ANDA (November 1999) http://www.fda.gov/cder/guidance/2766fnl.pdf
Meeting Minutes
Additional Material of the Container/Closure Systems Working Group
Back To Top
Excipients
(Chair) Robert Wiens
The Excipients WG is developing current practices for control of excipients and will explore ways for more efficient controls.
Draft Guidance for Industry on Drug Product: Chemistry, Manufacturing, and Controls Information (2003) http://www.fda.gov/cder/guidance/1215dft.pdf
“PQRI Survey of Pharmaceutical Excipient Testing and Control Strategies Used by Excipient Manufacturers, Excipient Distributors, and Drug-Product Manufacturers”, Pharmaceutical Technology Sep 2, 2006, pg. 90, Gregory Larner, David R. Schoneker, Catherine Sheehan, Rajendra Uppoor, Phyllis Walsh, Robert Wiens.
Joint Position Paper From Excipient Manufacturers, Drug Product Manufacturers and USP on Pharmaceutical Excipient Testing and Control Strategies; Based on a PQRI Survey and Workshop (PDF)
Work Plan
Meeting Minutes
Back To Top
Particle Size Distribution: Mass Balance Working Group
(Chairs) Bruce Wyka and Terry Tougas
The Aerodynamic Particle Size Distribution Mass Balance WG is evaluating the suitability of specifications for mass balance obtained from cascade impactor measurements, as recommended in draft FDA guidances for orally inhaled and intranasal drug products.
Draft Guidance for Industry-Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documents (1998). http://www.fda.gov/cder/guidance/2180dft.pdf
Final Guidance for Industry-Nasal Spray Drug Products Chemistry, Manufacturing, and Control Documentation (2002) http://www.fda.gov/cder/guidance/4234fnl.pdf
Work Plan
Establishment of the Appropriate Use of the Particle Size Distribution Mass
Balance Determined by Cascade Impactor for Orally Inhaled and Nasal Drug
Products (PDF)
Meeting Minutes
-
February 22, 2006 (PDF)
-
October 11, 2005 (PDF)
-
September 22, 2005 (PDF)
-
August 17, 2005 (PDF)
-
June 10, 2005 (PDF)
-
April 29, 2005 (PDF)
-
October 13, 2004 (PDF)
-
September 20, 2004 (PDF)
-
September 20, 2004 (PDF)
-
August 17, 2004 (PDF)
-
July 20, 2004 (PDF)
-
June 28, 2004 (PDF)
-
June 4, 2004 (PDF)
-
June 1, 2004 (PDF)
-
March 19, 2004 (PDF)
-
February 23, 2004 (PDF)
-
August 5, 2003 (PDF)
-
July 23, 2003 (PDF)
-
July 2, 2003 (PDF)
-
June 4, 2003 (PDF)
-
May 14, 2003 (PDF)
-
April 3, 2003 (PDF)
-
March 3, 2003 (PDF)
-
January 24, 2003 (PDF)
-
December 19, 2002 (PDF)
-
November 8, 2002 (PDF)
-
October 21, 2002 (PDF)
-
September 24-25, 2002 (PDF)
-
July 29, 2002 (PDF)
-
July 3, 2002 (PDF)
-
May 30, 2002 (PDF)
-
May 13, 2002 (PDF)
-
March 25, 2002 (PDF)
-
February 25, 2002 (PDF)
-
February 14, 2002 (PDF)
-
January 29, 2002 (PDF)
-
December 18, 2001 (PDF)
-
November 30, 2001 (PDF)
-
November 19, 2001 (PDF)
Back To Top
Particle Size Distribution: Profile Comparisons Working Group
(Chair) David Christopher
The Aerodynamic Particle Size Distribution Profile Comparisons WG is developing a robust statistical method (and evaluating that proposed in a draft FDA guidance) for establishing in vitro bioequivalence of aerosol particle size distributions of orally inhaled and intranasal drug products.
Draft Guidance for Industry-Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (1999, second draft 2003) http://www.fda.gov/cder/guidance/5383DFT.doc
Work Plan
Investigation of an Optimized Chi-square Method for Comparing Particle
Size Distribution Profiles Obtained by Cascade Impactors with Specific
Reference to Equivalence Testing of Orally Inhaled and Pressurized Nasal
Drug Products
(PDF)
Meeting Minutes
-
January 12, 2007 (PDF)
-
December 11, 2006 (PDF)
-
September 18, 2006 (PDF)
-
August 28, 2006 (PDF)
-
July 31, 2006 (PDF)
-
July 10, 2006 (PDF)
-
June 15, 2006 (PDF)
-
May 22, 2006 (PDF)
-
April 12, 2006 (PDF)
-
March 7, 2006 (PDF)
-
January 9, 2006 (PDF)
-
December 14, 2005 (PDF)
-
December 1, 2005 (PDF)
-
November 16, 2005 (PDF)
-
October 19, 2005 (PDF)
-
October 3, 2005 (PDF)
-
July 13, 2005 (PDF)
-
May 25, 2005 (PDF)
-
May 11, 2005 (PDF)
-
April 13, 2005 (PDF)
-
March 23, 2005 (PDF)
-
March 2, 2005 (PDF)
-
February 16, 2005 (PDF)
-
January 12, 2005 (PDF)
-
December 15, 2004 (PDF)
-
October 27, 2004 (PDF)
-
September 22, 2004 (PDF)
-
July 7, 2004 (PDF)
-
June 23, 2004 (PDF)
-
June 6, 2004 (PDF)
-
May 26, 2004 (PDF)
-
May 13, 2004 (PDF)
-
April 27, 2004 (PDF)
-
March 30, 2004 (PDF)
-
March 15, 2004 (PDF)
-
March 9, 2004 (PDF)
-
March 3, 2004 (PDF)
-
February 2, 2004 (PDF)
-
January 13, 2004 (PDF)
-
December 19, 2003 (PDF)
-
August 5, 2003 (PDF)
-
July 29, 2003 (PDF)
-
June 26, 2003 (PDF)
-
May 5, 2003 (PDF)
-
April 2, 2003 (PDF)
-
October 30, 2002 (PDF)
-
October 24, 2002 (PDF)
-
October 7, 2002 (PDF)
-
September 16, 2002 (PDF)
-
September 12, 2002 (PDF)
-
August 30, 2002 (PDF)
-
August 9, 2002 (PDF)
-
July 18, 2002 (PDF)
-
June 27, 2002 (PDF)
-
June 4, 2002 (PDF)
-
May 14, 2002 (PDF)
-
April 17, 2002 (PDF)
-
March 15, 2002 (PDF)
-
January 28, 2002 (PDF)
-
January 22, 2002 (PDF)
-
December 6, 2001 (PDF)
-
November 26, 2001 (PDF)
-
November 16, 2001 (PDF)
Additional Materials of the Profile Comparison Working Group
PSD Profile Summary Discussion Comparison Subgroup
Back To Top
Leachables and Extractables
(Chair) Daniel Norwood
The Leachables and Extractables WG is developing reporting and qualification thresholds for leachables in orally inhaled and intranasal drug products.
Draft Guidance for Industry-Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documents (1998). http://www.fda.gov/cder/guidance/2180dft.pdf
Final Guidance for Industry-Nasal Spray Drug Products Chemistry, Manufacturing, and Control Documentation (2002) http://www.fda.gov/cder/guidance/4234fnl.pdf
Work Plan
Development of Scientifically Justifiable Thresholds for Leachables and Extractables (PDF)
Meeting Minutes
-
January 14, 2005 (PDF)
-
December 17, 2004 (PDF)
-
December 1, 2004 (PDF)
-
October 7, 2004 (PDF)
-
October 5, 2004 (PDF)
-
October 1, 2004 (PDF)
-
September 28, 2004 (PDF)
-
August 9, 2004 (PDF)
-
July 13, 2004 (PDF)
-
July 9, 2004 (PDF)
-
May 17, 2004 (PDF)
-
April 20, 2004 (PDF)
-
April 16, 2004 (PDF)
-
April 1, 2004 (PDF)
-
March 24, 2004 (PDF)
-
March 16, 2004 (PDF)
-
February 2, 2004 (PDF)
-
January 23, 2004 (PDF)
-
November 19, 2003 (PDF)
-
November 10, 2003 (PDF)
-
September 23, 2003 (PDF)
-
September 10, 2003 (PDF)
-
August 19, 2003 (PDF)
-
August 4, 2003 (PDF)
-
July 2, 2003 (PDF)
-
April 30, 2003 (PDF)
-
April 16, 2003 (PDF)
-
April 9, 2003 (PDF)
-
April 7, 2003 (PDF)
-
April 3, 2003 (PDF)
-
March 7, 2003 (PDF)
-
February 28, 2003 (PDF)
-
February 26, 2003 (PDF)
-
February 21, 2003 (PDF)
-
January 29, 2003 (PDF)
-
January 28, 2003 (PDF)
-
January 23, 2003 (PDF)
-
January 9, 2003 (PDF)
-
December 11, 2003 (PDF)
-
December 17, 2002 (PDF)
-
December 4, 2002 (PDF)
-
November 12, 2002 (PDF)
-
October 24, 2002 (PDF)
-
September 20, 2002 (PDF)
-
July 26, 2002 (PDF)
-
July 3, 2002 (PDF)
-
July 2, 2002 (PDF)
-
June 20, 2002 (PDF)
-
May 31, 2002 (PDF)
-
May 8, 2002 (PDF)
-
April 22, 2002 (PDF)
-
April 9, 2002 (PDF)
-
February 14, 2002 (PDF)
-
January 22, 2002 (PDF)
-
December 17, 2001 (PDF)
-
November 30, 2001 (PDF)
-
November 16, 2001 (PDF)
Back To Top
Blend Uniformity Working Group
Meeting Minutes
Back To Top
Stability Shelf Life Working Group
Meeting Minutes
Back To Top
Thresholds and Best Practices for Leachables and Extractables in Parenteral and Ophthalmic Drug Products Working Group
Diane Paskiet, Chair
Doug Ball, Toxicology Co-chair
Dennis Jenke, Chemistry Co-chair
Membership Criteria (PDF)
Proposal (PDF)
Meeting Minutes
Back To Top
Impurities
(Chair) Chun Chow Chan
The Impurities WG is determining appropriate methods and extent of characterization for impurities as a function of the stage of product development.
ICH Q3A http://www.fda.gov/cder/guidance/Q3Cfnl.pdf
Impurities Working Group Survey
Meetings Minutes
March 11, 2004 (PDF)
February 10, 2004 (PDF)
December 9, 2003 (PDF)
November 12, 2003 (PDF)
October 16, 2003 (PDF)
September 23, 2003 (PDF)
August 12, 2003 (PDF)
July 14, 2003 (PDF)
July 14, 2003 (PDF)
June 10, 2003 (PDF)
February 11, 2003 (PDF)
January 14, 2003 (PDF)
December 10, 2002 (PDF)
October 30, 2002 (PDF)
October 8, 2002 (PDF)
August 20, 2002 (PDF)
March 12, 2002 (PDF)
January 29, 2002 (PDF)
January 11, 2002 (PDF)
December 11, 2001 (PDF)
November 6, 2001 (PDF)
August 21, 2001 (PDF)
July 11, 2001 (PDF)
June 28, 2001 (PDF)
May 24, 2001 (PDF)
April 17, 2001 (PDF)
March 20, 2001
Back To Top
Physical Attributes/Particle Size Working Group
(Chair) Sharon Snorek
The Physical Attributes/ Particle Size WG is discussing test methods and specification-setting for particles of active pharmaceutical ingredients in oral dosage forms.
ICH Q2A http://www.fda.gov/cder/guidance/ichq2a.pdf
ICH Q2B http://www.fda.gov/cder/guidance/1320fnl.pdf
ICH Q6A http://www.fda.gov/OHRMS/DOCKETS/98fr/122900d.pdf
Work Plan
Drug Substance Particle Size Work Plan (PDF)
Meeting Minutes
Back To Top
Specifications/BACPAC Working Group
(Chair) Angelos Dovletoglou
The Specifications/ BACPAC WG is considering a core set of specifications (test, analytical methods, and acceptance criteria) that would assure the identity, strength, quality, purity and potency of a drug substance following a manufacturing change after the final intermediate.
Guidance for Industry BACPAC I: Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation http://www.fda.gov/cder/guidance/3629fnl.htm
Meeting Minutes
Back To Top
Process Robustness Working Group
The Process Robustness WG is developing an industry-wide understanding of factors that influence complexity and robustness of processes for oral solid dosage forms.
Work Plan
Process Robustness Work Plan (PDF)
Back To Top
Post Approval Changes for Sterile Products Working Group
Post Approval Changes for Sterile Products WG will work to develop a listing of common changes which occur in the manufacturing of sterile products and will provide recommendations on the risk associated with these changes.
Post Approval Changes for Sterile Products Working Group (PDF)
Back To Top
Case Studies for Risk Management Working Group
The Case Studies for Risk Management WG will develop specific examples where different risk models have been used within the spectrum of pharmaceutical industry, spanning pharmaceutical development through manufacturing (“case studies”), and training in how to use these models.
Back To Top
Biologicals Inspection Survey Working Group
The Biologicals Inspection Survey WG will evaluate and assess Team Biologicals inspections by conducting a survey of industry.
Results of a Survey of Biological Drug and Device Industries Inspected by FDA under the Team Biologics Program (PDF)
Back To Top
Aseptic Processing Working Group
Work Plan
Aseptic Processing Work Plan (PDF)
Meeting Minutes
Back To Top
Sequential Design Working Group
The Sequential Design WG is developing appropriate statistical methods to justify the approach of using sequential design methods to permit the pooling of pharmacokinetic data from multiple studies to justify a bioequivalance of a product.
Back To Top
Dissolution Working Group
Dissolution WG is considering a core set of dissolution methods that would be applied to all products to aid in the identification of a dissolution method that is predictive of in vivo behavior for a given compound.
Back To Top
BCS Class III Biowaiver Working Group
BCS Class III Biowaiver WG is collecting and analyzing data to determine the viability of biowaivers for BCS Class III compounds.
PQRI Survey Of Oral Ionizable Drugs (PDF)
PQRI Survey OF Oral Ionizable Drugs (MS Word)
Back To Top
Immediate Release Oral Drug Products Working Group
Meeting Minutes
Back To Top
|